B
Barbara Fisher
Researcher at University of Western Ontario
Publications - 119
Citations - 30412
Barbara Fisher is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Radiation therapy & Temozolomide. The author has an hindex of 40, co-authored 116 publications receiving 26509 citations. Previous affiliations of Barbara Fisher include London Health Sciences Centre & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Does stereotactic body radiation improve outcomes compared to conventional radiation for liver cancer patients?
Michael Lock,Ronald Chow,Aruni Jayatilaka,Meghan D. Plotnick,Robert E. Stephens,Barbara Fisher,Eugene Wong,S. Gaede +7 more
TL;DR: In this paper , the authors compared outcomes of patients who received moderately hypofractionated and hypoffractionated radiotherapy treatments for liver tumours, and found that a larger proportion of patients were alive at the 2-year time point.
Phase I S tudy o f T opotecan P lus C ranial R adiation f or Glioblastoma M ultiforme: R esults o f R adiation T herapy Oncology G roup T rial 9 507
TL;DR: Toxicity was acceptable at an IV topotecan dose of 1.5 mg/m 2 /d administered daily for 5 days every 21 days for three cycles of cranial radiotherapy for glioblastoma multiforme.
Journal ArticleDOI
Cerebellar diffuse midline glioma, h3k27m altered in a fifty-five-year-old patient
TL;DR: A 55-year-old woman who presented with a 2.5-month history of nausea, vomiting and gait impairment was admitted to hospice. Imaging revealed a partially cystic, enhancing lesion in the midline of the cerebellum as mentioned in this paper .
Journal ArticleDOI
Ctni-16. nrg-rtog 9802 observation arm - long term result
Fabio M. Iwamoto,Mei Yin C. Polley,Edward G. Shaw,Jan C. Buckner,Geoffrey R. Barger,Stephen W. Coons,Peter Ricci,Mark R. Gilbert,Paul Brown,Keith M. Stelzer,C. Leland Rogers,John H. Suh,Christopher J. Schultz,Steven P. Howard,Barbara Fisher,Michelle M. Kim,Jiayi Huang,Michael G. Haddock,Minhee Won,Minesh P. Mehta +19 more
TL;DR: The Radiation Therapy Oncology Group 9802 trial as discussed by the authors was a phase III trial for patients with centrally confirmed LGG (WHO grade II) who were randomized to radiotherapy (RT) +/- PCV.